Bruker Corp
NASDAQ:BRKR

Watchlist Manager
Bruker Corp Logo
Bruker Corp
NASDAQ:BRKR
Watchlist
Price: 57.07 USD 1.51% Market Closed
Market Cap: 8.7B USD
Have any thoughts about
Bruker Corp?
Write Note

Bruker Corp
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bruker Corp
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Bruker Corp
NASDAQ:BRKR
Current Portion of Long-Term Debt
$32.8m
CAGR 3-Years
-33%
CAGR 5-Years
156%
CAGR 10-Years
47%
Thermo Fisher Scientific Inc
NYSE:TMO
Current Portion of Long-Term Debt
$4.1B
CAGR 3-Years
501%
CAGR 5-Years
44%
CAGR 10-Years
3%
Danaher Corp
NYSE:DHR
Current Portion of Long-Term Debt
$1.2B
CAGR 3-Years
456%
CAGR 5-Years
2%
CAGR 10-Years
33%
Mettler-Toledo International Inc
NYSE:MTD
Current Portion of Long-Term Debt
$185.8m
CAGR 3-Years
51%
CAGR 5-Years
31%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Current Portion of Long-Term Debt
$1.2B
CAGR 3-Years
137%
CAGR 5-Years
66%
CAGR 10-Years
50%
No Stocks Found

Bruker Corp
Glance View

Market Cap
8.7B USD
Industry
Life Sciences Tools & Services

Bruker Corporation stands as a pivotal player in the life sciences and analytical instrument markets, renowned for its innovative technologies that empower researchers and laboratories worldwide. Founded in 1960, Bruker has consistently focused on developing advanced scientific instruments that enhance the understanding of biological processes and materials. Through its diverse portfolio, which includes high-performance mass spectrometry, nuclear magnetic resonance (NMR), and microscopy systems, Bruker addresses critical challenges in fields such as drug discovery, environmental analysis, and clinical diagnostics. With a commitment to innovation, the company is well-positioned to benefit from ongoing trends in healthcare and life sciences, promising an exciting growth trajectory for potential investors. As the global scientific community increasingly turns to precise analytics and advanced diagnostics, Bruker’s offerings align perfectly with the burgeoning demand for cutting-edge research tools. The company has cultivated strong relationships with academic institutions, government agencies, and pharmaceutical companies, ensuring a robust customer base. Furthermore, with a focus on sustainability and reducing environmental impact, Bruker is tapping into new market segments that prioritize eco-friendly solutions. With a solid financial foundation, a history of strategic acquisitions, and ongoing investments in research and development, Bruker Corporation represents a compelling opportunity for investors looking to gain exposure to the dynamic fields of life sciences and analytical technology.

BRKR Intrinsic Value
70.32 USD
Undervaluation 19%
Intrinsic Value
Price

See Also

What is Bruker Corp's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
32.8m USD

Based on the financial report for Sep 30, 2024, Bruker Corp's Current Portion of Long-Term Debt amounts to 32.8m USD.

What is Bruker Corp's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
47%

Over the last year, the Current Portion of Long-Term Debt growth was -73%. The average annual Current Portion of Long-Term Debt growth rates for Bruker Corp have been -33% over the past three years , 156% over the past five years , and 47% over the past ten years .

Back to Top